Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹6,456Cr
Rev Gr TTM
Revenue Growth TTM
6.97%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

INDIAGLYCO
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -3.6 | -14.7 | 15.7 | 63.3 | 49.5 | 40.6 | 24.1 | 7.8 | -6.8 | 7.4 | 13.6 | 13.0 |
| 523 | 589 | 679 | 802 | 822 | 843 | 845 | 852 | 717 | 891 | 935 | 927 |
Operating Profit Operating ProfitCr |
| 15.5 | 14.5 | 12.3 | 11.3 | 11.3 | 13.0 | 12.1 | 12.7 | 16.9 | 14.4 | 14.4 | 15.9 |
Other Income Other IncomeCr | 6 | 12 | 12 | 9 | 10 | 14 | 15 | 19 | 13 | 20 | 14 | 3 |
Interest Expense Interest ExpenseCr | 26 | 28 | 29 | 31 | 33 | 36 | 40 | 44 | 45 | 45 | 49 | 47 |
Depreciation DepreciationCr | 30 | 21 | 28 | 26 | 26 | 28 | 28 | 27 | 33 | 34 | 38 | 41 |
| 46 | 64 | 50 | 54 | 56 | 76 | 63 | 71 | 82 | 91 | 84 | 91 |
| 6 | 13 | 12 | 12 | 13 | 15 | 14 | 15 | 18 | 17 | 19 | 23 |
|
Growth YoY PAT Growth YoY% | -40.6 | 85.4 | 61.2 | -16.8 | 6.0 | 18.1 | 30.8 | 36.5 | 51.7 | 21.3 | 30.9 | 18.9 |
| 6.4 | 7.4 | 4.9 | 4.6 | 4.6 | 6.2 | 5.2 | 5.8 | 7.4 | 7.0 | 6.0 | 6.1 |
| 6.4 | 8.3 | 6.1 | 6.7 | 6.8 | 9.8 | 8.0 | 9.2 | 10.3 | 11.8 | 10.5 | 10.8 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| -13.3 | -9.9 | 7.5 | 21.4 | 10.6 | -18.5 | -15.3 | 23.8 | -7.6 | 24.3 | 14.4 | 8.8 |
| 2,456 | 2,146 | 2,263 | 2,711 | 2,940 | 2,457 | 2,049 | 2,613 | 2,355 | 2,892 | 3,257 | 3,470 |
Operating Profit Operating ProfitCr |
| 4.8 | 7.7 | 9.4 | 10.7 | 12.4 | 10.2 | 11.6 | 8.9 | 11.2 | 12.2 | 13.6 | 15.3 |
Other Income Other IncomeCr | -16 | -44 | 7 | 22 | 16 | 8 | 16 | 264 | 63 | 42 | 61 | 50 |
Interest Expense Interest ExpenseCr | 163 | 146 | 127 | 125 | 143 | 97 | 83 | 70 | 100 | 121 | 164 | 185 |
Depreciation DepreciationCr | 89 | 69 | 72 | 73 | 76 | 78 | 80 | 80 | 94 | 101 | 115 | 147 |
| -144 | -81 | 45 | 147 | 213 | 113 | 120 | 369 | 165 | 223 | 292 | 347 |
| -55 | -24 | 10 | 51 | 81 | 38 | 11 | 39 | 24 | 50 | 61 | 77 |
|
| 45.1 | 35.9 | 161.7 | 175.4 | 37.4 | -43.6 | 45.9 | 201.8 | -57.2 | 22.6 | 33.5 | 16.9 |
| -3.4 | -2.4 | 1.4 | 3.2 | 4.0 | 2.7 | 4.7 | 11.5 | 5.3 | 5.3 | 6.1 | 6.6 |
| -28.6 | -9.2 | 5.7 | 15.6 | 21.4 | 18.5 | 21.3 | 54.9 | 22.8 | 27.9 | 37.3 | 43.5 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| 266 | 687 | 721 | 814 | 932 | 1,003 | 1,138 | 1,761 | 1,870 | 2,020 | 2,225 | 2,363 |
Current Liabilities Current LiabilitiesCr | 2,399 | 1,836 | 1,902 | 1,665 | 1,725 | 1,984 | 1,733 | 1,749 | 1,865 | 2,375 | 2,321 | 2,025 |
Non Current Liabilities Non Current LiabilitiesCr | 459 | 1,065 | 838 | 911 | 1,097 | 1,068 | 1,217 | 1,110 | 1,092 | 1,191 | 1,599 | 1,738 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 1,781 | 1,277 | 1,132 | 1,079 | 1,385 | 1,595 | 1,328 | 1,607 | 1,646 | 1,945 | 1,816 | 1,675 |
Non Current Assets Non Current AssetsCr | 1,373 | 2,343 | 2,361 | 2,343 | 2,399 | 2,491 | 2,792 | 3,023 | 3,212 | 3,672 | 4,360 | 4,482 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | -171 | 1,231 | 302 | 502 | 147 | 343 | 137 | 116 | 326 | 439 | 362 |
Investing Cash Flow Investing Cash FlowCr | 175 | -78 | -40 | -103 | -128 | -151 | -148 | 76 | -330 | -503 | -736 |
Financing Cash Flow Financing Cash FlowCr | -4 | -1,168 | -263 | -399 | 3 | -216 | 11 | -189 | -1 | 90 | 354 |
|
Free Cash Flow Free Cash FlowCr | -53 | 1,137 | 260 | 373 | 9 | 193 | -11 | -264 | -109 | -103 | -391 |
| 192.9 | -2,166.4 | 862.0 | 519.8 | 110.9 | 458.6 | 125.8 | 35.2 | 230.9 | 253.5 | 156.8 |
CFO To EBITDA CFO To EBITDA% | -138.0 | 692.2 | 127.8 | 155.1 | 35.3 | 123.1 | 51.2 | 45.5 | 110.2 | 109.0 | 70.9 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 252 | 263 | 496 | 1,400 | 866 | 659 | 1,290 | 3,135 | 1,900 | 2,343 | 3,437 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 14.1 | 14.5 | 6.5 | 5.8 | 9.8 | 9.2 | 15.2 | 13.5 | 14.9 |
Price To Sales Price To Sales | 0.1 | 0.1 | 0.2 | 0.5 | 0.3 | 0.2 | 0.6 | 1.1 | 0.7 | 0.7 | 0.9 |
Price To Book Price To Book | 0.8 | 0.4 | 0.7 | 1.7 | 0.9 | 0.6 | 1.1 | 1.8 | 1.0 | 1.1 | 1.5 |
| 15.4 | 8.1 | 6.0 | 6.5 | 3.9 | 5.3 | 8.7 | 16.0 | 9.8 | 8.8 | 10.3 |
Profitability Ratios Profitability Ratios |
| 36.5 | 36.9 | 35.8 | 34.0 | 38.3 | 32.5 | 35.3 | 33.0 | 40.3 | 34.8 | 36.1 |
| 4.8 | 7.7 | 9.4 | 10.7 | 12.4 | 10.2 | 11.6 | 8.9 | 11.2 | 12.2 | 13.6 |
| -3.4 | -2.4 | 1.4 | 3.2 | 4.0 | 2.7 | 4.7 | 11.5 | 5.3 | 5.3 | 6.1 |
| 0.9 | 3.3 | 10.1 | 17.1 | 19.5 | 10.8 | 8.8 | 15.4 | 8.8 | 10.1 | 11.0 |
| -29.8 | -7.9 | 4.7 | 11.4 | 13.8 | 7.2 | 9.3 | 18.4 | 7.4 | 8.4 | 10.2 |
| -2.8 | -1.6 | 1.0 | 2.8 | 3.5 | 1.8 | 2.6 | 7.1 | 2.9 | 3.1 | 3.7 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Company Overview**
India Glycols Limited (IGL), established in **1983**, is a leading Indian manufacturer and innovator in **bio-based specialties, performance chemicals, potable spirits, biofuels, plant-based APIs, and nutraceuticals**. Headquartered in Kashipur, Uttarakhand, IGL operates three integrated manufacturing facilities in **Kashipur, Gorakhpur, and Dehradun**, spread across approximately **360 acres**, and exports to **over 40 countries**. The company has evolved from a glycols producer to a diversified, sustainability-driven enterprise, positioning itself at the forefront of green chemistry, circular economy initiatives, and value-added product innovation.
---
### **Business Segments & Revenue Split (FY25 Estimate)**
As of November 2025, IGL’s business is structured into four core segments:
1. **Potable Spirits (71.19%) – ₹6,434 crores**
- Leading player in **branded country liquor** in **Uttar Pradesh and Uttarakhand**.
- Core brands: *Amazing Vodka*, *Soulmate Blu Whisky*, *Zumba Lemoni Rum*, *Bunty Bubli* (three-time highest-selling liquor brand).
- Also launched **cranberry-flavored vodka** and introduced **IGL Zumba Lemoni™**, a citrus rum.
- Supply licenses in key states and presence in **paramilitary** (CSD) and **institutional channels**.
2. **Bio-Based Specialities & Performance Chemicals (14.84%) – ₹1,341 crores**
- Flagship products: **Bio-Monoethylene Glycol (Bio-MEG)**, glycol ethers, bio-polymers, industrial gases, green solvents.
- Produces **100% of India’s commercial bio-based MEG** – used in PET for sustainable packaging and textiles.
- Unique capability: **Only Indian plant producing both Ethylene Oxide (EO) and Liquid CO₂** for medical sterilization gas (*IGL-STERI GAS*).
- Key target sectors: oil & gas, automotive, personal care, pharma, textiles, industrial cleaning.
3. **Biofuels / Power Alcohol (11.55%) – ₹1,044 crores**
- Supplies **grain-based ethanol** to **Oil Marketing Companies (OMCs)** under the **Ethanol Blending Programme (EBP)**.
- Distillery capacities: **500 KLPD (Kashipur)** and **310 KLPD (Gorakhpur)**.
- Expansion underway at Gorakhpur to **190 KLPD biofuel capacity** (expected Q1 FY26).
4. **Ennature Biopharma (2.42%) – ₹219 crores**
- Focus: **Plant-based APIs, nutraceuticals, phytochemicals, and health supplements**.
- Key products: **Thiocolchicoside** (global leadership), **nicotine & nicotine salts**, **Maxicuma®**, **Xanthogreen™**.
- Supplies **pure nicotine** to international NRT (nicotine replacement therapy) manufacturers.
---
### **Key Strategic Developments (Q4 2025)**
#### 1. **Sustained Growth in Potable Spirits & Partnerships**
- IGL secured rights to distribute its in-house spirits brands — **Zumba Lemoni**, **Soulmate Blu**, and **Amazing Vodka** — in **Kerala**, a high-potential market. Plans are underway to launch an **in-house Brandy**.
- Continues to co-pack **Bacardi’s portfolio** (including **Breezer**, **Carta Blanca**) at its Kashipur unit under a full-service arrangement (distillation, maturation, logistics).
- Strategic partnership with **Amrut Distilleries** enables IGL to **manufacture, bottle, market, and sell** premium Amrut brands (e.g., **Maqintosh White & Black Label**, **Bejois XO**) in **North India** on a royalty basis.
- Maqintosh launched in **Delhi-NCR** in July 2024; achieved **>10% market share** within months.
- **Paramilitary segment:** Now supplies five IMFL brands across 19 states and ranks among **top four suppliers** via centralized procurement.
- Plans to enter the **Canteen Stores Department (CSD)** with **Soulmate Whisky** and **Zumba Limon**, targeting long-term defense force demand.
#### 2. **Innovation & Expansion in Specialty Chemicals**
- Became the **first company globally to commercialize bio-based amines**, including **Bio-Monoethanolamine** for cosmetics, in collaboration with **L’Oreal**.
- Collaborating with **Scientific Design Inc. (US)** for **bio-glycols**, **LanzaTech** for **C-Smart® alcohol**-based specialty chemicals, and **Clariant** (JV) for **bio-ethoxylates**.
- Uses **Sulzer Chemtech’s continuous process** for glycol ethers — **only Indian manufacturer** with this technology.
- Launched **"iGreen" solvent platform** (bio-esters, bio-ether esters) for agricultural and personal care applications.
- Developing a pipeline of **over 30 new green molecules**, including:
- Bio-polymers (from guar/polygalactomannans)
- Specialty bio-amines
- Carbon-smart (C-Smart) derivatives
- Green plasticizers
- APIs and nutraceuticals
#### 3. **Ennature Biopharma: Strengthening Branded & Regulated Portfolios**
- Projected **FY25 EBITDA of ₹525 crores**, with net profit of **₹231 crores**, reflecting strong underlying performance.
- Facing **export headwinds** due to **declining nicotine demand** (Europe, Turkey) and **seed shortages**, but pivoting toward:
- **Clinical validation & claim substantiation** of nutraceuticals.
- **Branded ingredient strategy** in **US and EU markets** (e.g., **Maxicuma® – nanotized curcumin**).
- **Regulatory filings** in USFDA and EU to support direct market access.
- Maintains **germplasm bank** for over **100 herb species** (artemisia, stevia, marigold) with **contract farming agreements**.
- Aims to **launch branded nutraceuticals directly in US/Europe**, potentially improving margins significantly.
#### 4. **Biofuels & Green Energy Momentum**
- Now actively supplying **bio-ethanol from grain-based distilleries** to OMCs — entering a new revenue stream.
- Government **ethanol blending target of 20% by 2025** creates sustained tailwinds.
- Flexible ethanol sourcing: dynamically allocates self-produced **grain/molasses-based ENA** across **spirits, chemical intermediates, and biofuels** based on profitability.
- Exploring **Sustainable Aviation Fuel (SAF)** as a future growth area — though in “wait and watch” mode due to regulatory uncertainty.
#### 5. **Sustainability & Circular Economy Leadership**
- A global pioneer in **carbon-captured chemistry**: uses **ethanol from recycled industrial emissions** (via LanzaTech) to produce **MEG and derivatives**.
- Achieves **near-zero liquid/solid discharge** via **supercritical CO₂ extraction** and **closed-loop biomass energy systems**.
- Only Indian company producing **Medical Grade STERI-GAS** (EO + CO₂ mixture) under **ISO 13485:2016 certification**.
- Sold **1,796 MT** of STERI Gas in FY25 — **25% YoY growth** from 1,431 MT.
---
### **Corporate Strategy & Business Model**
- **Modular expansion model** allows for **incremental CAPEX** and **scalable capacity additions** based on demand.
- **Restructuring into three independent business verticals**:
1. **Chemicals**: Green/specialty chemicals, bio-glycols, industrial gases
2. **Spirits**: IMFL, country liquor, bio-alcohol
3. **Ennature Biopharma**: APIs, nutraceuticals, phytochemicals
- This facilitates targeted investments and value unlocking.
#### Strategic Focus Areas:
- **Premiumization**: Launching higher-value spirits and expanding in defense/paramilitary channels.
- **Export-led growth**: Focus on **regulatory-compliant, science-backed nutraceuticals and green chemicals** in North America, Europe, Far East.
- **Green differentiation**: Marketing **Bio-MEG**, **bio-glycols**, and **carbon-smart chemicals** as low-carbon alternatives.
- **Customer-driven innovation**: 60–70% of new specialty chemicals developed through **long-term customer collaboration** (e.g., with **Unilever, Lululemon, Migros**).
---
### **Global Recognition & Competitive Strengths**
- **Three-Star Export House** (Government of India).
- Supplies **global multinationals** including **Coca-Cola**, **Bacardi**, **Unilever**, **Diageo**, **Pernod Ricard**, **Reliance**, and **HUL**.
- Strong R&D infrastructure:
- DSIR-recognized labs in **Dehradun & Kashipur**
- **Pilot plants**, **plug-flow reactors**, **bio-solvent and bio-amine R&D**
- **Nanotechnology platforms** (Maxicuma®, SCEMOD™, LIMAN™)
- **Proprietary technology stack** spanning **bio-ethylene**, **carbon capture**, and **green extraction**.
---
### **Challenges & Risks**
- **Commoditization risk** in APIs (Thiocolchicoside, nicotine) due to competition and price pressure from new entrants.
- **Volatility in glycol ether markets** due to **low-cost Chinese/Russian imports**.
- **Guar gum market dependence** on crude oil prices and fracking activity in the US.
- **Regulatory uncertainty** in state excise policies (e.g., Delhi, UP).